Jeffrey Bennett, AAN 2022: Challenges in the treatment of aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder

Aquaporin 4-immunoglobulin G (AQP4-IgG) plays a major role in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD). Prof. Jeffrey Bennett (University of Colorado School of Medicine, Aurora, CO, USA) discusses the challenges in the treatment of NMOSD.

Questions:

1. What are the challenges in the treatment of neuromyelitis optica spectrum disorder (NMOSD)? (0:14)
2. What is the role of aquaporin 4-immunoglobulin G (AQP4-IgG) in the pathogenesis of NMOSD, and what percentage of patients are seropositive  for this antibody? (1:17)

Disclosures: Jeffrey Bennett is/has been a consultant for Roche/Genentech, Chugai Pharmaceuticals, Horizon, Mitsubishi-Tanabe, Reistone Bio, Abbvie, Clene Neuroscience, Alexion-AstraZeneca Rare Disease, and Beigene; and has received grant/research support from National Institutes of Health, Novartis, Mallinckrodt Pharmaceuticals, and Alexion-AstraZeneca Rare Disease; and is on the advisory board for Roche/Genentech, and Alexion-AstraZeneca Rare Disease.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of AAN 2022